DOW JONES22,118.36+481.58 2.23%
S&P 5002,601.99+60.52 2.38%
NASDAQ7,705.51+203.13 2.71%

Needham Maintains Buy on Nabriva Therapeutics, Lowers Price Target to $5

Needham analyst Alan Carr maintains Nabriva Therapeutics (NASDAQ:NBRV) with a Buy and lowers the price target from $10 to $5.

Benzinga · 03/13/2020 12:16

Needham analyst Alan Carr maintains Nabriva Therapeutics (NASDAQ:NBRV) with a Buy and lowers the price target from $10 to $5.